date:Apr 22, 2014
s that FDA will not likely resolve the ECJ issue on its own, at least for now.
As a practical matter, if courts dismiss these ECJ cases on primary jurisdiction grounds until FDA resolves the issue, the cases pretty much disappear, Friede explained. Depending on ones perspective, that may or may not be a good thing.